Search Results for “acquisition” – media

Pumis announces equity acquisition agreement with BioNTech

According to the terms of the agreement, BioNTech will acquire 100% of Pumis’ issued share capital for a prepayment of $800 million (approximately RMB 5.781 billion) (subject to customary adjustment of the acquisition price), primarily in cash and a portion of American Depositary Shares (ADS). In addition, BioNTech will pay an additional milestone payment of up to $150 million (approximately RMB 1.084 billion) when Pumis meets the milestone conditions agreed upon by both parties. The transaction is expected to be completed in the first quarter of 2025, subject to customary delivery conditions and regulatory approvals. After the completion of this transaction, BioNTech will acquire full rights to the Pumis candidate drug pipeline and its bispecific antibody drug development platform, further expanding its business scope in China; Pumis Zhuhai will serve as the BioNTech China R&D center to conduct related R&D research; The Pumis Nantong production base, which meets international standards, ...
- Source: drugdu
- 44
- November 19, 2024
26.7 billion! Boston Scientific completes blockbuster acquisition

On November 15, local time, Boston Scientific announced the completion of its acquisition of medical technology company Axonics, Inc. The transaction was priced at $71 per share, with an equity value of $3.7 billion (equivalent to approximately RMB 26.76 billion). Boston Scientific expects that the transaction will have little impact on adjusted earnings per share in 2024 and 2025, and will increase thereafter. Axonics focuses on the development and commercialization of differentiated devices for the treatment of urinary and intestinal dysfunction. Its core products include sacral nerve modulation systems and urethral swelling hydrogels. Axonics is an important competitor of Medtronic in the field of sacral nerve modulation. This field was previously an absolute dominance of Medtronic. After the approval of Axonics products, it gradually expanded its market territory. Data shows that the company has a 27% market share in the sacral nerve modulation market. Axonics ranked second in the list ...
- Source: drugdu
- 41
- November 19, 2024
China’s time-honored brands, mergers and acquisitions accelerate

Recently, Beijing Tong Ren Tang issued an announcement on foreign investment, stating that its holding subsidiary Beijing Tong Ren Tang Commercial intends to sign a “Share Transfer Agreement” with Honghui Technology, Daopei Hongde, Honghui Pharmaceutical, Wang Desheng and Wang Aixiao, and intends to pay about 105 million yuan to acquire Honghui Technology’s 51% stake in Honghui Pharmaceutical. As a pharmaceutical and medical device operating company, Honghui Pharmaceutical was established in 1994 and is mainly engaged in pharmaceutical research and development, pharmaceutical production and sales, and medical device operations. The performance in the first half of 2024 showed that Honghui Pharmaceutical achieved revenue of 844 million yuan and net profit of 25.5713 million yuan (unaudited). In 2023, Honghui Pharmaceutical achieved a net profit of 228 million yuan (unaudited). At present, Honghui Pharmaceutical is still a long way from catching up with last year’s full-year net profit. Tong Ren Tang is a ...
- Source: drugdu
- 61
- November 6, 2024
What are the considerations behind the acquisition of Yikuai Pharmaceutical by Yaoshibang?

On October 15, Yaoshibang issued an announcement that it had signed a transaction agreement to acquire 100% of the equity of Yikuai Pharmaceutical, with a total consideration of RMB 1.035 billion, including a cash consideration of RMB 420 million and a share consideration of RMB 615 million. In the pharmaceutical industry, where mergers and acquisitions are common, this transaction with a total price of RMB 1 billion has attracted considerable attention. The reason is that this is not only the first large-scale acquisition of Yaoshibang, a pharmaceutical B2B e-commerce unicorn, since its listing, but also related to Yaoshibang’s own financial situation. Amid the tightening of listing, Yaoshibang successfully rang the bell on the Hong Kong Stock Exchange in June 2023. However, as a “digital enterprise that deeply cultivates the outpatient market” that went public at a loss, Yaoshibang had just turned a profit when it handed in its full-year performance ...
- Source: drugdu
- 73
- October 19, 2024
Dental laser equipment boss, bankruptcy and acquisition

On October 9, 2024, Biolase, which occupies the top spot in the world’s dental laser equipment, announced that it has signed an agreement to sell the majority of the company’s assets to rival Sonendo for $14 million. Biolase Company of United States, the world’s leading oral laser expert, has long been committed to the research and development and manufacturing of full-function lasers, with a global laser market share of 70%. However, due to long-term losses, the stock price continued to be depressed, and it was delisted from the Nasdaq in June this year and declared bankruptcy on October 1. The buyer of the acquisition, Sonendo, a dental giant dedicated to root canal treatment devices, sued Biolase in 2023 for a patent dispute, claiming no less than $59 million in damages. This acquisition not only marks the end of an era for the giant Biolase, but also announces the end of ...
- Source: drugdu
- 65
- October 14, 2024
The China Securities Regulatory Commission encourages cross-border mergers and acquisitions of unprofitable assets, and a new path for Biotech to land in the capital market?

Wu Qing, chairman of the China Securities Regulatory Commission, said at a press conference of the State Council that in order to further stimulate the vitality of the M&A and restructuring market, the CSRC has studied and formulated the “Opinions on Deepening the Reform of the M&A and Restructuring Market of Listed Companies” (“M&A Six”, hereinafter referred to as the “Opinions”), including supporting the transformation and upgrading of listed companies in the direction of new quality productivity, encouraging industrial integration, improving regulatory tolerance, and improving the transaction efficiency of the restructuring market. Among them, it is clear that it will vigorously support listed companies to carry out cross-industry mergers and acquisitions and acquisitions of unprofitable assets based on transformation and upgrading. This means that unprofitable biotech companies may usher in a new path to land in the capital market. At the meeting, Wu Qing said that mergers and acquisitions are ...
- Source: drugdu
- 77
- October 5, 2024
The CSRC encourages cross-border mergers and acquisitions of unprofitable assets, a new path for Biotech to enter the capital market?

On September 24, Wu Qing, chairman of the CSRC, said at a press conference of the State Council that in order to further stimulate the vitality of the merger and reorganization market, the CSRC has studied and formulated the “Opinions on Deepening the Reform of the Merger and Reorganization Market of Listed Companies” (“Six Mergers and Acquisitions”, hereinafter referred to as the “Opinions”), including supporting listed companies to transform and upgrade to new quality productivity, encouraging industrial integration, improving regulatory tolerance, and improving the transaction efficiency of the reorganization market. Among them, it is clearly stated that listed companies are strongly supported to carry out cross-industry mergers and acquisitions and acquisitions of unprofitable assets based on transformation and upgrading. This means that unprofitable biotech companies may usher in a new path to enter the capital market. At the meeting, Wu Qing said that mergers and acquisitions are major events in ...
- Source: drugdu
- 93
- September 27, 2024
Dental equipment leader, completes important acquisition

Dental equipment pioneer Henry Schein announced that it has completed the acquisition of Shield Healthcare Inc. Shield Healthcare Inc. is a device company that directly provides home care medical products to patients. Henry Schein announced this transaction last year. 01 Enters the field of household appliances In August 2023, Henry Schein announced that he had signed an agreement to acquire a majority stake in Shield Healthcare, Inc. On the basis of Henry Schein’s acquisition of Prism Medical Products LLC in 2021, Shield Healthcare will expand Henry Schein’s existing medical business by providing diversified product series, including incontinence, urology, ostomy, enteral nutrition, advanced wound care and diabetes products. In addition, it will provide patients with continuous blood glucose monitoring devices directly at home. As the healthcare industry continues to shift towards home care, we have expanded our business of directly providing medical products to patients through our partnership with Shield Healthcare, ...
- Source: drugdu
- 74
- September 24, 2024
Acquisition of Loss-Making Company to Consolidate Plasma Station Resources

Recently, TianTan Bio (600161.SH) announced that its controlling subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. (referred to as “Chengdu Rongsheng”) intends to acquire 100% of the shares of Wuhan Zhongyuan Ruide Biological Products Co., Ltd. (referred to as “Zhongyuan Ruide”), a wholly-owned subsidiary of CSL Behring Asia Pacific Limited (“CSL Asia Pacific”), for a total amount of $185 million (approximately 1.317 billion yuan). After the completion of this transaction, Zhongyuan Ruide will become a controlled subsidiary of TianTan Bio, and its financial statements will be consolidated. TianTan Bio indicated that it will add a new blood product production enterprise and five operational blood plasma collection stations. According to reporters from China Business Journal, Zhongyuan Ruide was acquired by CSL Asia Pacific between 2017 and 2018 through its subsidiary CSL Behring. However, after seven years, CSL Asia Pacific has chosen to sell at a discounted price. Additionally, the company is currently in ...
- Source: drugdu
- 107
- September 14, 2024
Big Servier Acquisition Pays Off as FDA Approves Drug for Two Types of Rare Brain Cancer

The FDA approved Servier Pharmaceuticals’ Voranigo as a treatment for two types of low-grade gliomas. The drug, which is projected to become a blockbuster product, comes from Servier’s $1.8 billion acquisition of Agios Pharmaceuticals’ oncology business. By Frank VinluanA Servier Pharmaceuticals drug designed to penetrate the brain to hit its targets is now FDA approved for treating two rare types of brain cancer. The FDA approval announced Tuesday covers the treatment of adults and adolescents 12 and older who have Grade 2 astrocytoma or oligodendroglioma. The drug, vorasidenib, may be prescribed after surgery, as long as the cancers have mutations to the IDH1 or IDH2 enzymes the once-daily pill is designed to inhibit. The FDA said this regulatory decision marks the agency’s first for a systemic therapy for these cancers driven by either the IDH1 or IDH2 mutations. France-based Servier, which has its U.S. headquarters in Boston, will commercialize its ...
- Source: drugdu
- 89
- August 10, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.